Dr Floor J Backes from The James Cancer Hospital and Solove Research Institute in Columbus, Ohio, Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, and Dr Ritu Salani from the David Geffen School of Medicine at UCLA in Los Angeles, California, discuss key clinical trial data, clinical cases and questions surrounding the management of endometrial cancer using immunotherapy. CME information and select publications here ....
May 14, 2026•1 hr 30 min•Season 26Ep. 234
Dr Nikhil I Khushalani from the Moffitt Cancer Center in Tampa, Florida, discusses available and novel treatment strategies for nonmelanoma skin cancers. NCPD information and select publications here .
May 07, 2026•1 hr 4 min•Season 26Ep. 233
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer. CME information and select publications here ....
May 03, 2026•18 min•Season 26Ep. 232
Dr Aditya Bardia from the University of California Los Angeles and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the use of oral SERDs in the management of breast cancer. CME information and select publications here .
Apr 30, 2026•57 min•Season 26Ep. 231
Dr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung cancer and summarize major advances in the treatment landscape reported over the past year. CME information and select publications here .
Apr 27, 2026•57 min•Season 26Ep. 230
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Sym...
Apr 24, 2026•17 min•Season 26Ep. 229
Dr Andrew J Armstrong from the Duke Cancer Institute in Durham, North Carolina, and Dr Scott T Tagawa from Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss the selection and sequencing of therapy for patients with prostate cancer and summarize major advances in the treatment landscape over the past year. CME information and select publications here .
Apr 23, 2026•58 min•Season 26Ep. 228
Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML. CME information and select publications here .
Apr 20, 2026•59 min•Season 26Ep. 227
Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer. CME information and select publications here .
Apr 17, 2026•27 min•Season 26Ep. 226
Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer. CME information and select publications here .
Apr 16, 2026•1 hr•Season 26Ep. 225
Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia, and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publications here .
Apr 15, 2026•28 min•Season 26Ep. 224
Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer. CME information and select publications here .
Apr 14, 2026•58 min•Season 26Ep. 223
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer. CME information and select publications here ....
Apr 13, 2026•15 min•Season 26Ep. 222
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma. CME information and select publications here .
Apr 10, 2026•25 min•Season 26Ep. 221
Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management. CME information and select publications here ....
Apr 08, 2026•16 min•Season 26Ep. 220
Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application. CME information and select publications here .
Apr 07, 2026•28 min•Season 26Ep. 219
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium....
Apr 03, 2026•22 min•Season 26Ep. 218
Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida, Dr Soo J Park from the UC San Diego Moores Cancer Center in California, Dr Vishal Anil Patel from the GW Cancer Center in Washington, DC, and Dr Evan Wuthrick, also from Moffitt Cancer Center, discusses recent updates on available and novel treatment strategies for nonmelanoma skin cancers. CME information and select publications here .
Apr 02, 2026•2 hr 14 min•Season 26Ep. 217
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia. CME information and select publications here .
Apr 01, 2026•25 min•Season 26Ep. 216
Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer. CME information and select publications here .
Mar 30, 2026•1 hr 29 min•Season 26Ep. 215
Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors. CME information and select publications here ....
Mar 28, 2026•1 hr 16 min•Season 26Ep. 214
Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publications here ....
Mar 27, 2026•33 min•Season 26Ep. 213
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer. CME information and select publications here ....
Mar 26, 2026•17 min•Season 26Ep. 212
Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic’s Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladder cancer, alongside their perspectives on clinical application and disease management. CME informati...
Mar 25, 2026•1 hr 58 min•Season 26Ep. 211
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Ca...
Mar 24, 2026•25 min•Season 26Ep. 210
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma. CME information and select publications here .
Mar 23, 2026•24 min•Season 26Ep. 209
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia. CME information and select publications here .
Mar 21, 2026•29 min•Season 26Ep. 208
Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management. CME information and select publications here ....
Mar 19, 2026•22 min•Season 26Ep. 207
Dr Lajos Pusztai from Yale Cancer Center in New Haven, Connecticut, discusses recent developments with circulating tumor DNA assays in the management of breast cancer. CME information and select publications here .
Mar 18, 2026•30 min•Season 26Ep. 206
Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application. CME information and select publications here .
Mar 16, 2026•17 min•Season 26Ep. 205
